NIH Director Francis Collins awarded Leadership in Personalized Medicine Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FRANCIS COLLINS, director of the NIH, was awarded the Leadership in Personalized Medicine Award by the Personalized Medicine Coalition. He will be presented the award during the Personalized Medicine Conference at Harvard Medical School Nov. 19.

In his letter nominating Collins for the award, Harvard Medical School professor Raju Kucherlapati, noted that Collins “has made sustained and critical contributions for the establishment of personalized medicine.”

Collins earned national recognition in 1989, more than a decade before the complete sequencing of the human genome, for his team’s discovery of the gene responsible for cystic fibrosis. He then served as the director of the National Human Genome Research Institute, where he was the overall project manager of the international Human Genome Project, which produced a complete map of the human genome in 2003.

He also played a key role in the passage of the Genetic Information Nondiscrimination Act in 2008, which has helped to ensure that the insights from his extraordinary achievements and those of many others are not used for discriminatory purposes.

President Barack Obama nominated him as NIH director in 2009, proclaiming that his work had already “changed the very ways we consider our health and examine disease.” As director, Collins’ advocacy helped shape the Precision Medicine Initiative, which was announced earlier this year as part of the president’s budget proposal for fiscal year 2016.

“I see a day in the not too distant future when every person will have his or her genome sequenced and other important data collected as a routine part of medical care with individualized strategies developed for diagnosing, treating and preventing their disease,” said Collins. “I know that the PMC shares this vision and I am truly honored to receive this award from an organization that continues to pursue the vision with such great passion.”

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login